Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 12:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ozanimod Clear all
Terminated Phase 3 Interventional Results available

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

NCT03467958
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
190
States / cities
Peoria, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 142 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

NCT04528290
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 18, 2026, 12:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

NCT03665610
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 18, 2026, 12:04 PM EDT
Active, not recruiting No phase listed Observational

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

NCT05605782
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

NCT02576717
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
2,494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Berkeley, California • Fresno, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 18, 2026, 12:04 PM EDT
Recruiting No phase listed Observational

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

NCT06311123
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

NCT04639115
View directory record Official record
Conditions
Liver Diseases, Digestive System Diseases
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01647516
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 73 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
10
States / cities
Anaheim, California • La Jolla, California • Oceanside, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 18, 2026, 12:04 PM EDT
Terminated Phase 3 Interventional

Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
RPC-1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

NCT04978298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Rasigiline, Phenelzine, Ozanimod
Other · Drug
Lead sponsor
Celgene
Industry
Eligibility
25 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 18, 2026, 12:04 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

An Examination of Cognitive Fatigue Using Functional Neuroimaging

NCT04885894
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Zeposia
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 18, 2026, 12:04 PM EDT
Withdrawn Phase 4 Interventional

A Lactation Study in Women Receiving Treatment With Ozanimod

NCT06181630
View directory record Official record
Conditions
Lactating Women, Breastfed Infants
Interventions
Breast milk, plasma, and blood samples
Diagnostic Test
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

NCT01628393
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Berkeley, California • Fresno, California • Sacramento, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

NCT02531126
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 18, 2026, 12:04 PM EDT
Terminated Phase 3 Interventional Results available

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440372
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
107
States / cities
Peoria, Arizona • North Little Rock, Arkansas • Camarillo, California + 84 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 18, 2026, 12:04 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02531113
View directory record Official record
Conditions
Crohn's Disease
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 18, 2026, 12:04 PM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 18, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 18, 2026, 12:04 PM EDT